What is the long-term trend for NovoCure's payments to acquire held-to-maturity securities?

Over 4 years (2021 to 2025), NovoCure's payments to acquire held-to-maturity securities has grown at a -6.6% compound annual growth rate (CAGR), from $1.08B to $821.08M.

NovoCure NVCR Payments to Acquire Held-to-Maturity Securities

Payments to Acquire Held-to-Maturity Securities at other companies

Columbia Financial, Inc.CLBK

$0-100%

BKBK

$3.04B+141%

PNC Financial ServicesPNC

$3.34B+10,677%

Ollie's Bargain Outlet Holdings, Inc.OLLI

$58.14M-51.1%

PNC Financial ServicesPNC

$3.34B+10,677%

Apollo Global ManagementAPO

$1M-99.8%

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireHeldToMaturitySecurities.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's payments to acquire held-to-maturity securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's payments to acquire held-to-maturity securities?: NovoCure (NVCR) reported payments to acquire held-to-maturity securities of $97.1M in Q1 2026.
How has NovoCure's payments to acquire held-to-maturity securities changed year-over-year?: NovoCure's payments to acquire held-to-maturity securities decreased by 16.2% year-over-year, from $115.86M to $97.1M.
What is the long-term trend for NovoCure's payments to acquire held-to-maturity securities?: Over 4 years (2021 to 2025), NovoCure's payments to acquire held-to-maturity securities has grown at a -6.6% compound annual growth rate (CAGR), from $1.08B to $821.08M.